Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2018 Jul 20;157:151–158. doi: 10.1016/j.antiviral.2018.07.010

The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo

Daniel Todt a,b,1, Nora Moeller b,1, Dimas Praditya b, Volker Kinast b, Martina Friesland b, Michael Engelmann b, Lieven Verhoye c, Ibrahim M Sayed c,d, Patrick Behrendt b,e, Viet Loan Dao Thi f,g, Philip Meuleman c, Eike Steinmann a,b,∗
PMCID: PMC7113770  PMID: 30036559

Abstract

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genus Orthohepevirus in the family Hepeviridae. HEV infections are the common cause of acute hepatitis but can also take chronic courses. Ribavirin is the treatment of choice for most patients and type I interferon (IFN) has been evaluated in a few infected transplantation patients in vivo. However, no effective and specific treatments against HEV infections are currently available.

In this study, we evaluated the natural compound silvestrol, isolated from the plant Aglaia foveolata, and known for its specific inhibition of the DEAD-box RNA helicase eIF4A in state-of-the-art HEV experimental model systems. Silvestrol blocked HEV replication of different subgenomic replicons in a dose-dependent manner at low nanomolar concentrations and acted additive to ribavirin (RBV). In addition, HEV p6-based full length replication and production of infectious particles was reduced in the presence of silvestrol. A pangenotypic effect of the compound was further demonstrated with primary isolates from four different human genotypes in HEV infection experiments of hepatocyte-like cells derived from human embryonic and induced pluripotent stem cells. In vivo, HEV RNA levels rapidly declined in the feces of treated mice while no effect was observed in the vehicle treated control animals. In conclusion, silvestrol could be identified as pangenotypic HEV replication inhibitor in vitro with additive effect to RBV and further demonstrated high potency in vivo. The compound therefore may be considered in future treatment strategies of chronic hepatitis E in immunocompromised patients.

Keywords: Hepatitis E virus (HEV), Silvestrol, Antiviral activity, Host target, Replication, Humanized mice

Highlights

  • •

    The natural compound silvestrol is a potent inhibitor of HEV replication.

  • •

    HEV infection of laboratory and primary isolates could be inhibited by silvestrol.

  • •

    Silvestrol demonstrated high potency in human liver chimeric mice.

  • •

    Targeting translation initiation could be a novel antiviral strategy for the treatment of chronic hepatitis E.

1. Introduction

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and is classified as a member of the genus Orthohepevirus within the Hepeviridae family. Worldwide, hepatitis E is the leading cause for acute viral hepatitis. With approximately 20 million people infected with HEV causing approx. 3.3 million cases of acute illness leading to nearly 44.000–70.000 deaths per year, this pathogen has substantial impact on humans life and needs to be socioeconomically considered (Wedemeyer et al., 2012). At least four human-pathogenic HEV genotypes exist (gt1-4). Genotype 1 and 2 solely infect humans and are mainly present in developing areas causing water-borne outbreaks. Pregnant women harbor a high risk for a fatal outcome during HEV gt1 infection with mortality rates up to 30% in the last trimester (Kamar et al., 2017). In contrast, gt 3 and 4 are zoonotic pathogens with their main reservoir in pigs, wild boars and deer (Sayed et al., 2015). Having contact with these animals or consumption of contaminated meat-products are major risk factors for acquiring an HEV infection. The latter genotypes are responsible for most of infections in industrialized nations. HEV gt 3 infections in humans are usually self-limiting, but can evolve also to chronicity in immunosuppressed individuals with the risk for the development of liver cirrhosis and eventually hepatic decompensation with the need for liver transplantation (Behrendt et al., 2014). Current therapies used to treat HEV infections including ribavirin and interferon-alpha have severe side effects and are contra-indicated in pregnant woman. Furthermore, virus isolates have been recently identified that possess lower ribavirin sensitivity leading to higher treatment failure rates (Debing et al., 2014, 2016; Todt et al., 2016a, 2016b). Therefore, efficacious and safe antiviral treatments against HEV are urgently needed.

In a screening approach for novel HEV inhibitors, we identified the natural compound silvestrol. Silvestrol is a structurally unique cyclopenta[b]benzofuran that can be isolated from the plant Aglaia foveolata belonging to the family of Meliacae (Kim et al., 2007). It is described as a highly efficient, non-toxic and specific inhibitor of the DEAD-box RNA helicase eIF4A (Bordeleau et al., 2008), which is part of the eIF4F complex that drives cap-dependent translation initiation in eukaryotes (Silvera et al., 2010). In this study, we show that silvestrol inhibits the replication of different HEV gts in a dose-dependent manner at low nanomolar concentrations. This anti-HEV activity was further observed in infection experiments with laboratory and primary isolates in human liver cells and in vivo using humanized mice. These results identify silvestrol as a novel natural compound that blocks HEV replication and could therefore be part of an antiviral strategy for the treatment of HEV infections.

2. Materials and methods

2.1. Compounds and reagents

Silvestrol was received from MedChem Express (Monmouth Junction, NJ, USA). Ribavirin (RBV) was received from Sigma Aldrich, St. Louis, MO, USA. All compounds were stored and diluted according to manufacturer's recommendations.

2.2. Cell culture

The human liver cell lines HepG2 and Huh7.5 were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (GE Healthcare), 100 μg/mL of streptomycin and 100 IU/mL of penicillin (Invitrogen), 2 mM L-glutamine and 1% nonessential amino acids (Invitrogen) (DMEM complete). The HepG2/C3A subclone was cultured in Eagle's minimum essential medium (MEM with glutamine, Invitrogen), 10% ultra-low IgG FCS (Invitrogen), 2 mM L-glutamine, 100 μg/mL gentamicin, 1 mM sodium pyruvate and nonessential amino acids (Invitrogen). HepG2 and HepG2/C3A cells were further grown on rat collagen-coated (SERVA Electrophoresis GmbH, Heidelberg, Germany) culture plates. Cells were kept at 37 °C in a 5% (vol/vol) CO2 incubator.

2.3. HEV constructs and in vitro transcription

A plasmid construct containing the full-length HEV genome (Kernow-C1 p6 clone, gt3; GenBank accession no. JQ679013) and four constructs harboring a subgenomic HEV sequence coupled to a Gaussia luciferase reporter gene were used to generate HEV in vitro transcripts as previously described (Drave et al., 2016). One of the constructs derives from the gt1 Sar55/S17 strain (based on clone pSK E2, GenBank accession no. AF444002) and two other constructs are based on the Kernow-C1 p6 genome of which one contains the polymerase mutation G1634R (Todt et al., 2016a). The other gt3 Gaussia luciferase coupled construct derives from the G3-HEV83-2-27 virus (gt3; GenBank accession no. AB740232) and was a kind gift of the laboratory of Takaji Wakita. Capping of all constructs was performed using Ribom7G Cap Analog (Promega, Madison, WI, USA). A HCV JFH1 subgenomic replicon was used as reference construct as described (Anggakusuma et al., 2015).

2.4. HEV primary isolates

Primary isolates gt1 strain Sar-55 (1.21 × 108 viral RNA copies/mL) and gt2 Mexico-14 (1.65 × 106 viral RNA copies/mL) in 10% fecal suspension from infected macaques and Kernow-C1 P1 supernatant from HepG2 cells (2.3 × 106 viral RNA copies/mL), were a kind gift from Suzanne U. Emerson (Emerson et al., 2004). Primary isolates gt3 strain US-2 (1.6 × 104 viral RNA copies/mL) and gt4 strain TW6196E (9.39 × 103 viral RNA copies/mL) in 10% fecal suspension from infected pigs were a kind gift from Xiang-Jin Meng (Virginia Tech) (Feagins et al., 2008).

2.5. Generation of human pluripotent stem cell-derived hepatocyte-like cells and HEV infection

ESC or iPSC were differentiated into HLCs as previously described (Wu et al., 2018).

2.6. Infection of humanized mice

Human liver chimeric mice (humanized mice) were generated by transplantation of primary human hepatocytes (donor HH223, Corning) into homozygous uPA+/+-SCID mice, as previously described (Meuleman et al., 2005). Humanized mice were inoculated via intrasplenic route with a filtered fecal suspension containing 2,8 × 105 IU of the genotype 1 HEV strain Sar-55 (generously provided by Dr. Suzanne Emerson, NIH, USA). Four weeks after inoculation, mice were treated with a daily intraperitoneal dose of 0.3 mg/kg silvestrol, formulated in 30% 2-hydroxypropyl-β-cyclodextrin (Sigma-Aldrich), or vehicle only. Stool samples were collected on a daily basis and viral RNA was detected and quantified in mouse 10% stool suspensions using a previously described RT-qPCR (Sayed et al., 2017).

2.7. Statistical analysis

Dose-dependent inhibition of replication was plotted using GrahPad Prism v7.03 for Windows (La Jolla California USA, www.graphpad.com) and IC50, IC90 and CC50 were calculated using the four-parameter log-logistic model. Statistical significance of differences of means was calculated using one-way ANOVA followed by Dunnett's multiple comparison test were indicated. P values < 0.05 were considered significant (n.s. non-significant).

3. Results

3.1. Antiviral activity of silvestrol against subgenomic HEV replication

HEV and other viral mRNAs contain highly structured 5′-UTRs that need to be translated by the cellular translation machinery in order to promote viral protein synthesis. Silvestrol is a specific inhibitor of the host encoded eIF4A, an RNA helicase that promotes 5′ cap-dependent translation initiation (Gingras et al., 1999). To analyse the effect of silvestrol against HEV, we first transfected the human hepatoma cell line Huh7.5 with different HEV subgenomic replicons, in which a part of the ORF2 was replaced by a Gaussia luciferase reporter gene. These include the HEV gt 3 construct p6 (Shukla et al., 2011), a variant (G1634R) thereof with increased replication fitness (Debing et al., 2014; Todt et al., 2016a), the gt3-based wild boar isolate 83-2-27 (Shiota et al., 2013) and the gt 1 strain Sar55 harboring an S17 insertion in the ORF1 like the p6 strain (Shukla et al., 2011). As depicted in Fig. 1 A, incubation of silvestrol for 24 h resulted in a dose-dependent inhibition of HEV replication with inhibitory concentrations 50 (IC50) of 4–6.6 nM for the different HEV constructs (Fig. 1A and Table 1 ). For the known HEV inhibitor RBV, 1000-fold higher concentrations in μM range were needed to inhibit HEV replication (IC50 8–12 μM, Fig. 1A and Table 1). For the gt1 replicon an IC50 of 43 μM was observed for RBV (Fig. 1A and Table 1). HCV was employed as a reference virus and was less susceptible to silvestrol as translation initiation occurs cap-independent via an internal ribosomal entry site (IRES) (Fig. 1A). Cell viability was determined by an MTT assay, in which the enzymatic activity started to decrease at higher concentrations, but did not reach a cytotoxic concentration 50 (CC50) in line with reported data (Cencic et al., 2009; Biedenkopf et al., 2017) (Fig. 1A). Additionally, determination of viable cells under silvestrol treatment demonstrated no significant reductions (Fig. 1B). Treatment of silvestrol for 42 h resulted in even lower IC50 values for example 2.9 nM for the p6 strain with a CC50 value of 24.8 nM (Fig. 1C and Table 1), resulting in a selectivity index of about 8.6. Longer incubation times in the presence of silvestrol resulted in decreased cell viability (data not shown). Overall, RBV and cell viability profiles at 42 h were similar in comparison to the shorter treatment (Fig. 1C and D). Next, the inhibitory effect of silvestrol was evaluated in the full-length p6 clone in Huh7.5 cells. To visualize HEV antigen expression, we performed indirect immunofluorescence staining of the structural capsid protein ORF2. As depicted in Fig. 1E, ORF2 positive cells were highly reduced in the high dose (10 nM) silvestrol and RBV-treated cells (Fig. 1E). In summary, the natural compound silvestrol demonstrates an antiviral activity against different HEV gts at non-toxic concentrations.

Fig. 1.

Fig. 1

Open in a new tab

Silvestrol inhibits Hepatitis E virus (HEV) replication. Depicted is the dose-dependent inhibition of replication of transfected HEV replicons in Huh7.5 after silvestrol or ribavirin (continuous x-axes) treatment for 24 h (A) and 42 h (C). Reduction in replication was determined via reporter luciferase read-out and normalized to the respective DMSO treated control (y-axes). Three genotype 3 replicons and one genotype 1 replicon were employed and compared to a control replicon based on hepatitis C virus JFH1 (solid lines, see legend for color coding). Cell viability was monitored via MTT assay and is shown as dotted line. In addition, antiproliferative properties of silvestrol (medium concentration: 10 nM and high concentration: 100 nM) were assessed via visual cell counting after trypan blue staining and compared to ribavirin treated (50 μM) and untreated cells (B, D) (n.s. non-significant). E) Immunofluorescence staining of HEVp6 transfected Huh7.5 cells treated with silvestrol (low concentration: 2.5 nM and medium concentration: 10 nM), ribavirin or DMSO 4 h after transfection for 42 h.

Table 1.

IC50, IC90 and CC50 values calculated for silvestrol and ribavirin in Huh7.5 transfected with the indicated replicons.

Replicon constructs Silvestrol [nM]
 Ribavirin [μM]
IC50 (CI) IC90 (CI) CC50 (CI) IC50 (CI) IC90 (CI) CC50 (CI)
24 h
HEVp6 4.43 (3.73–5.25) 64.69 (43.55–95.66) n.d. 8.16 (6.53–10.24) 244.44 (n.d.) n.d.
HEVp6
G1634R		 5.58 (4.99–6.24) 60.25 (46.68–77.51) 7.86 (6.69–9.23) 171.14 (n.d.)
HEV 83-2 6.19 (5.28–7.33) n.d. 11.90 (9.37–15.32) 524.19 (n.d.)
HEV
Sar55/S17		 6.65 (5.22–8.73) n.d. 43.08 (29.94–63.30) n.d.
HCV 24.29 (19.99–30.26) 127.80 (n.d.) 12.33 (9.60–15.93) 128.24 (n.d.)
42 h
HEVp6 2.87 (2.61–3.16) 27.28 (21.93–33.87) 24.84 (16.82–39.78) 6.90 (5.98–7.96) 50.38 (36.66–68.73) n.d.
HEVp6
G1634R		 3.29 (2.97–3.64) 28.82 (22.98–36.05) 9.69 (8.84–10.62) 70.99 (57.70–87.05)
HEV 83-2 4.49 (3.81–5.36) 27.66 (18.45-n.d.) 10.51 (9.27–11.93) 63.84 (48.23–83.94)
HEV
Sar55/S17		 3.17 (2.81–3.60) 52.80 (36.92-n.d.) 30.28 (25.67–36.92) n.d.
HCV 71.11 (n.d.) 517.83 (n.d) 62.48 (51.15–95.77) n.d.
Open in a new tab

n.d. not determined.

CI 95% confidence interval.

3.2. Inhibition of cell culture- and patient-derived HEV infection by silvestrol

Next, we evaluated the antiviral effect of silvestrol in HEV infection experiments using cell culture-derived infectious HEV (HEVCC) based on the p6 isolate (Dao Thi et al., 2016) in HepG2/C3A cells and patient-derived HEV of gts 1–4 in pluripotent stem cell-derived hepatocyte-like cells (HLCs) (Wu et al., 2018). At first, we evaluated the antiviral activity of silvestrol with the HEVp6 replicon in the HepG2/C3A cell line and observed a shift of the dose-response curves in comparison to Huh7.5 (suppl. Fig. 1). In case of the HEVCC infection assay, treatment setups with silvestrol with a concentration of 10, 20 and 50 nM between 24 h and 48 h, day 6 and day 7 or at both time intervals were carried out (Fig. 2 A). The experimental read out was the determination of infectious particle production in focus forming units (FFU/mL) from the cell lysate after the first round of infection (Fig. 2A). The inhibition of HEV replication was most prominent with the 20 nM and 50 nM treatment at the late time point (Fig. 2B). RBV treatment served as a control and demonstrated inhibitory effects in the late treatment and combinatory arms (Fig. 2B). For all silvestrol incubations cell viability was not reduced (Fig. 2C). Next, patient-derived HEV from gts 1–4 were used to infect HLCs and treated 24 h post-infection with silvestrol for 24 h (Fig. 2A). The inhibitory effect of the natural compound for non-adapted HEV isolates in non-carcinoma cell lines was confirmed in all major human pathogenic genotypes (Fig. 2D) without cytotoxicity (Fig. 2E). In conclusion, infection of hepatoma or HLC cells with different HEV isolates can be reduced by the treatment with silvestrol.

Fig. 2.

Fig. 2

Open in a new tab

Antiviral effect of silvestrol on cell culture derived infectious viral particles (HEVCC) and primary Hepatitis E virus (HEV) isolates. A) Assay setup: HEVCC based on HEVp6 or primary isolates of all genotypes were used to infect HepG2/C3A cells or hepatocyte-like cells (HLC). Twenty-four hours after infection (h p.i.), cells were treated in triplicates as indicated: a) 24 h–48 h (black bars in B-E); b) 6 d–7 d (white bars in B-C); c) 24 h–48 h and 6 d–7 d (gray bars in B-C) and lysed after 7 d p.i. Intracellular viruses obtained from freeze-thaw lysis were used to infect HepG2/C3A on 96 well plates and focus forming units (FFU) were counted after 7 d. B) Amount of infectious viral particles produced after treatment with different doses silvestrol (Sil) or 50 μM ribavirin (RBV), normalized to DMSO treated control. C) Cell viability was monitored via MTT assay and normalized to DMSO control. D) Reduction of HEV RNA copy numbers in HLCs infected with primary isolates of HEV genotypes 1–4 and HEVCC p6 after treatment with 10 nM silvestrol for 24 h 1 d p.i. (protocol a)), normalized to DMSO treated control. E) Cell viability was monitored via WST assay and normalized to DMSO control.

3.3. Inhibitory effects of silvestrol in human liver chimeric mice infected with HEV

Recently, several studies demonstrated that human liver chimeric mice can be infected with HEV and are useful tools for studying chronic HEV infection and antiviral drugs in vivo (Allweiss and Dandri, 2016; van de Garde et al., 2016; Sayed et al., 2017). To evaluate the antiviral effects of silvestrol in vivo, we chose based on previous work (Hwang et al., 2004; Saradhi et al., 2011), a silvestrol dose of 0.3 mg/kg, which was administered intraperitoneally to gt1 HEV (strain Sar-55) infected mice. Two mice were treated on a daily basis for ten days or six days respectively. Two additional served as control and were only treated with the vehicle. As depicted in Fig. 3 A, during the first days of treatment a rapid decline in HEV RNA was observed in the feces of all treated mice, while no effect was observed in the vehicle treated control animals (Fig. 3A). No changes in body weight of either animal were noted over the monitored period. Successful engraftment of human hepatocyte into the mouse livers was ensured by assessing human serum albumin levels in blood samples drawn before and after the treatment (supp. Fig. 2). These results implicate a strong antiviral effect of silvestrol in an HEV animal model system.

Fig. 3.

Fig. 3

Open in a new tab

Antiviral effect of silvestrol in Hepatitis E virus (HEV) infected human liver chimeric mice. A) HEV genotype 1 inoculated mice were treated with a daily intraperitoneal dose of 0.3 mg/kg silvestrol for ten (hexagon and diamond) or six days (circle and square) (red lines, two mice each) or vehicle only (triangles, black lines, two mice). Stool samples were collected on a daily basis and viral RNA was detected and quantified via RT-qPCR. B) The body weight of all animals was monitored over the time of the assay (coloring and shapes according to A)).

3.4. Combinatory activity of silvestrol with RBV

As RBV is the treatment of choice as off-label medication in chronically infected patients, we next performed combinatory treatments of silvestrol and RBV. Following electroporation of Huh7.5 cells with HEVp6 RNA genome harboring a Gaussia luciferase reporter gene, cells were grown in presence of various doses of silvestrol or RBV or their combinations. Luciferase assay read-out was performed after 24 h or 42 h of treatment. To characterize the interactions of the combined drugs, compounds were mixed at various molar ratios about matching their equipotent concentrations (silvestrol:RBV 1:250–1:32,000) and analyzed using CompuSyn software (Fig. 4 ). According to the method of Chou-Talalay (Chou and Talalay, 1984), combination indices (CI) were calculated. CIs for IC50, IC75 and IC90 after 24 h treatment range between 0.70 and 1.39. After 42 h of treatment, indices ranged from 0.76 to 1.42 indicating additive antiviral effects when combining silvestrol and ribavirin. This is also reflected by the positioning of the experimental data points in close proximity to the line of additivity in the isobologram (Fig. 4A, C) for all fractions. In addition, data were analyzed according to the Bliss independence model (Prichard Shipman 1990) and three-dimensional differential surface plots are depicted in Fig. 4B for the 24 h treatment and in Fig. 4D for the 42 h treatment. Here, we observed a minimal elevation above the plane after 24 h for the low silvestrol concentrations and a minor decrease below the plane after 42 h for the low silvestrol concentrations.

Fig. 4.

Fig. 4

Open in a new tab

Silvestrol has an additive antiviral effect when combined with ribavirin. Depicted is the dose-dependent inhibition of transfected HEV replicons after silvestrol and ribavirin combination treatment for 24 h (A-B) and 42 h (C-D). Reduction in replication was determined via reporter luciferase read-out and normalized to the respective DMSO treated control. A, C) Isobolograms with lines denoting the expected additive IC50 (left line), IC75 (middle line) and IC90 (right line) values for the drug combination as calculated from the monotherapies. The experimental IC50 (blue circles), IC75 (yellow squares) and IC90 (red triangles) are shown for the different drug ratios (dotted gray arrows). Symbols far left of the line of additivity indicate synergism, while symbols to its far right indicate antagonism. B, D) Three-dimensional surface plots representing potential differences between the actual experimental effects and the theoretical additive effects at various concentrations of the two compounds. Shading indicates different ranges above or below the expected value. An elevation above the zero planes indicates a synergistic effect, a decrease below the plane an antagonistic effect.

Taken together, these results suggest minimal changes in the mode of additivity for the combination of silvestrol and RBV at the different ratios employed. In this assay setup, both drugs showed additive effects in the inhibition of HEV replicon replication.

4. Discussion

Most of cellular and viral mRNAs rely on cap-dependent mRNA translation. The canonical mechanism of initiation commences with recognition of 5′ end m7GpppN cap structure by the eIF4F complex formed by the DEAD-box helicase eIF4A, the scaffolding protein eIF4G and the cap recognition factor eIF4E (Sonenberg and Hinnebusch, 2009). The natural compound silvestrol, which has been identified in this study as a novel HEV inhibitor, has been reported to have the ability of modulating translation by preventing ribosome loading onto mRNA templates by targeting this eIF4A eukaryotic initiation factor (Bordeleau et al., 2008; Cencic et al., 2009). Interestingly, Zhou et al. previously investigated the role of the eIF4F complex in HEV replication and found in line with the activity of silvestrol described here, that efficient replication of HEV requires the mRNA translation machinery eIF4A, eIF4G and eIF4E (Zhou et al., 2015). Programmed cell death 4 (PDCD4) and eIF4E-binding protein 1 (4E-BP1), the negative regulatory factors of this complex, exerted anti-HEV activities, which further illustrated the requirement for eIF4A and eIF4E in supporting HEV replication (Zhou et al., 2015). Therefore, molecules like silvestrol targeting these mRNA translation host factors open new perspectives for future antiviral strategies. Host-targeting agents (HTAs) are likely to exhibit a higher barrier of viral resistance development compared to specific viral targets. An antiviral activity for silvestrol has been described for Ebola virus replication (Biedenkopf et al., 2017). Inhibition of viral propagation by treatment with silvestrol occurred more rapidly than any effects on cellular functions and an IC50 lower than 1 nM was observed (Biedenkopf et al., 2017). Very recently, potent antiviral activities were also reported for coronaviruses including MERS-CoV and picornaviruses revealing broad-spectrum activities (Muller et al., 2018). For HEV, we observed also an antiviral activity at low nanomolar concentrations for the human gts 1 and 3, a gt3 swine isolate as well as for a viral variant, which was identified in HEV-infected patients and confers enhanced replication fitness (Fig. 1) (Debing et al., 2014; Todt et al., 2016a). HCV as cap-independent replication control was less susceptible to silvestrol, however, also the IRES-dependent translation machinery might require the help of additional translation initiation factors from the infected host cell (Thompson, 2012). The anti-HEV activity of silvestrol was subsequently confirmed in viral infection assays by determination of production of infectious particles after compound incubation. However, the overall antiviral activity of silvestrol was reduced in this assay compared to the replicon system in Huh7.5, as in HepG2/C3A cells higher concentration of the drug were needed (suppl. Fig. 1). In addition, a pangenotypic activity of silvestrol was observed using primary isolates from four different gts in HLCs derived from human embryonic and induced pluripotent stem cells (Fig. 2). HLCs offer an improved, physiologically relevant traceable system for studying the replication and antiviral response of primary HEV isolates (Wu et al., 2018).

Previously, silvestrol has been mainly characterized in antitumor models such as chronic lymphocytic leukemia, acute lymphocytic leukemia, mantle cell lymphoma and also hepatocellular carcinoma (Cencic et al., 2009; Lucas et al., 2009; Alinari et al., 2012; Kogure et al., 2013). Noteworthy, clinical efforts are underway to target specific components of the translation apparatus or unique mRNA translation elements in cancer therapeutics (Silvera et al., 2010; Bhat et al., 2015). Based on these in vivo studies, the inhibitory effect of silvestrol was additionally investigated in humanized mice infected with gt1 HEV, which showed a reduction of viral loads in the first few days of treatment (Fig. 3). This proof of concept validation in vivo should guide further silvestrol-based antiviral strategies, which could also involve combination treatments with RBV. Combining two drugs with distinct mechanisms of action involves the advantage of possible synergistic antiviral effects and decreased danger of the emergence of resistances, which is of exceptional importance in the therapeutic intervention for chronically HEV infected immunosuppressed patients (Debing et al., 2016; Todt et al., 2016a). In addition, synergistic antiviral effects imply the possibility to reduce the dose or dosing frequency of any of the two compounds, or even both, minimizing potential toxicity and adverse effects. Here, we employed two models to analyse interactions between silvestrol and RBV in combination according to the recommendations by Zhao and colleagues (Zhao et al., 2010). Both, combination indices and isobolograms calculated based on the Chou-Talalay method, as well as the three-dimensional surface plot determined using the Bliss independence model, suggest additive antiviral effects of the drugs (Fig. 4). As also slight deviations from the line of additivity and the planar plot were observed at extreme doses of antivirals (low and high effect levels), careful titration of the compounds in vitro and in vivo is recommended to identify the optimal ratio of the drugs for increased antiviral activity along with a reduced danger of the emergence of resistances and improved tolerability in clinical settings.

In summary, the natural compound silvestrol, which specifically targets the host factor eIF4A during cap-dependent translation initiation, could be identified as novel pangenotypic anti-HEV agent. Viral replication was inhibited by silvestrol in a dose-dependent manner at low nanomolar concentrations in different HEV experimental model systems including HEV primary isolates and HEV-infected humanized mice. Thus, silvestrol may be considered in future treatment strategies of chronic hepatitis E in immunocompromised patients.

Disclosure statement

The authors declare no conflict of interest.

Funding

E.S. was supported by the Helmholtz Centre for Infection Research and by the German Ministry of Education and Research (BMBF) through a GINAICO grant 16GW0105 and a an Exploration Grant from the Boehringer Ingelheim Foundation. P.M. was supported by the Research Foundation – Flanders (FWO-Vlaanderen; project G0D2715N and project VirEOS 30981113). I.M.S. is a recipient of a PhD fellowship provided by the Egyptian Government and the Ghent University. N.M. was supported by a stipend from the German Center for Infection Research (DZIF). V.L.D.T was supported by a Helmsley postdoctoral fellowship at The Rockefeller University.

Acknowledgments

We are grateful to Charles Rice for Huh7.5 cells, to Suzanne Emerson for the hepatitis E virus p6 clone and Sar55 and Mexico isolate, to Xiang-Jin Meng for the US-2 and TW6196E isolate, Ali Brivanlou for RUES2 cells, Stephen Duncan for iPS.C3A cells, and to Takaji Wakita for the 83-2-27 clone. HEV-specific rabbit hyperimmune serum was kindly provided by R. Ulrich, Friedrich Loeffler Institute, Germany. Moreover, we thank all members of the Institute of Experimental Virology, Twincore, for helpful support, suggestions and discussions.

Footnotes

Appendix A

Supplementary data related to this article can be found at https://doi.org/10.1016/j.antiviral.2018.07.010.

Appendix A. Supplementary data

The following are the supplementary data related to this article:

Multimedia component 1
mmc1.pdf (270.3KB, pdf)
Multimedia component 2
mmc2.xml (194B, xml)

References

  1. Alinari L., Prince C.J., Edwards R.B., Towns W.H., Mani R., Lehman A., Zhang X., Jarjoura D., Pan L., Kinghorn A.D., Grever M.R., Baiocchi R.A., Lucas D.M. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin. Canc. Res. 2012;18(17):4600–4611. doi: 10.1158/1078-0432.CCR-12-0839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allweiss L., Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J. Hepatol. 2016;64(1 Suppl. l):S17–S31. doi: 10.1016/j.jhep.2016.02.012. [DOI] [PubMed] [Google Scholar]
  3. Anggakusuma, Romero-Brey I., Berger C., Colpitts C.C., Boldanova T., Engelmann M., Todt D., Perin P.M., Behrendt P., Vondran F.W., Xu S., Goffinet C., Schang L.M., Heim M.H., Bartenschlager R., Pietschmann T., Steinmann E. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology. 2015;62(3):702–714. doi: 10.1002/hep.27913. [DOI] [PubMed] [Google Scholar]
  4. Behrendt P., Steinmann E., Manns M.P., Wedemeyer H. The impact of hepatitis E in the liver transplant setting. J. Hepatol. 2014;61(6):1418–1429. doi: 10.1016/j.jhep.2014.08.047. [DOI] [PubMed] [Google Scholar]
  5. Bhat M., Robichaud N., Hulea L., Sonenberg N., Pelletier J., Topisirovic I. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 2015;14(4):261–278. doi: 10.1038/nrd4505. [DOI] [PubMed] [Google Scholar]
  6. Biedenkopf N., Lange-Grunweller K., Schulte F.W., Weisser A., Muller C., Becker D., Becker S., Hartmann R.K., Grunweller A. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Antivir. Res. 2017;137:76–81. doi: 10.1016/j.antiviral.2016.11.011. [DOI] [PubMed] [Google Scholar]
  7. Bordeleau M.E., Robert F., Gerard B., Lindqvist L., Chen S.M., Wendel H.G., Brem B., Greger H., Lowe S.W., Porco J.A., Jr., Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 2008;118(7):2651–2660. doi: 10.1172/JCI34753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cencic R., Carrier M., Galicia-Vazquez G., Bordeleau M.E., Sukarieh R., Bourdeau A., Brem B., Teodoro J.G., Greger H., Tremblay M.L., Porco J.A., Jr., Pelletier J. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One. 2009;4(4):e5223. doi: 10.1371/journal.pone.0005223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships. the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  10. Dao Thi V.L., Debing Y., Wu X., Rice C.M., Neyts J., Moradpour D., Gouttenoire J. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology. 2016;150(1):82–85. doi: 10.1053/j.gastro.2015.09.011. e4. [DOI] [PubMed] [Google Scholar]
  11. Debing Y., Gisa A., Dallmeier K., Pischke S., Bremer B., Manns M., Wedemeyer H., Suneetha P.V., Neyts J. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology. 2014;147(5):1008–1011. doi: 10.1053/j.gastro.2014.08.040. e7; quiz e15-6. [DOI] [PubMed] [Google Scholar]
  12. Debing Y., Ramiere C., Dallmeier K., Piorkowski G., Trabaud M.A., Lebosse F., Scholtes C., Roche M., Legras-Lachuer C., Lamballerie X., de Andre P., Neyts J. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J. Hepatol. 2016;65(3):499–508. doi: 10.1016/j.jhep.2016.05.002. [DOI] [PubMed] [Google Scholar]
  13. Drave S.A., Debing Y., Walter S., Todt D., Engelmann M., Friesland M., Wedemeyer H., Neyts J., Behrendt P., Steinmann E. Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells. J. Viral Hepat. 2016;23(7):512–521. doi: 10.1111/jvh.12515. [DOI] [PubMed] [Google Scholar]
  14. Emerson S.U., Nguyen H., Graff J., Stephany D.A., Brockington A., Purcell R.H. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J. Virol. 2004;78(9):4838–4846. doi: 10.1128/JVI.78.9.4838-4846.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Feagins A.R., Opriessnig T., Huang Y.W., Halbur P.G., Meng X.J. Cross-species infection of specific-pathogen-free pigs by a genotype 4 strain of human hepatitis E virus. J. Med. Virol. 2008;80(8):1379–1386. doi: 10.1002/jmv.21223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gingras A.C., Raught B., Sonenberg N. eIF4 initiation factors. effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 1999;68:913–963. doi: 10.1146/annurev.biochem.68.1.913. [DOI] [PubMed] [Google Scholar]
  17. Hwang B.Y., Su B.N., Chai H., Mi Q., Kardono L.B., Afriastini J.J., Riswan S., Santarsiero B.D., Mesecar A.D., Wild R., Fairchild C.R., Vite G.D., Rose W.C., Farnsworth N.R., Cordell G.A., Pezzuto J.M., Swanson S.M., Kinghorn A.D. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J. Org. Chem. 2004;69(10):3350–3358. doi: 10.1021/jo040120f. [DOI] [PubMed] [Google Scholar]
  18. Kamar N., Izopet J., Pavio N., Aggarwal R., Labrique A., Wedemeyer H., Dalton H.R. Hepatitis E virus infection. Nat. Rev. Dis. Primers. 2017;3:17086. doi: 10.1038/nrdp.2017.86. [DOI] [PubMed] [Google Scholar]
  19. Kim S., Hwang B.Y., Su B.N., Chai H., Mi Q., Kinghorn A.D., Wild R., Swanson S.M. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 2007;27(4B):2175–2183. [PMC free article] [PubMed] [Google Scholar]
  20. Kogure T., Kinghorn A.D., Yan I., Bolon B., Lucas D.M., Grever M.R., Patel T. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One. 2013;8(9) doi: 10.1371/journal.pone.0076136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lucas D.M., Edwards R.B., Lozanski G., West D.A., Shin J.D., Vargo M.A., Davis M.E., Rozewski D.M., Johnson A.J., Su B.N., Goettl V.M., Heerema N.A., Lin T.S., Lehman A., Zhang X., Jarjoura D., Newman D.J., Byrd J.C., Kinghorn A.D., Grever M.R. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009;113(19):4656–4666. doi: 10.1182/blood-2008-09-175430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Meuleman P., Libbrecht L., Vos R. de, Hemptinne B. de, Gevaert K., Vandekerckhove J., Roskams T., Leroux-Roels G. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology. 2005;41(4):847–856. doi: 10.1002/hep.20657. [DOI] [PubMed] [Google Scholar]
  23. Muller C., Schulte F.W., Lange-Grunweller K., Obermann W., Madhugiri R., Pleschka S., Ziebuhr J., Hartmann R.K., Grunweller A. Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antivir. Res. 2018;150:123–129. doi: 10.1016/j.antiviral.2017.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Saradhi U.V., Gupta S.V., Chiu M., Wang J., Ling Y., Liu Z., Newman D.J., Covey J.M., Kinghorn A.D., Marcucci G., Lucas D.M., Grever M.R., Phelps M.A., Chan K.K. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J. 2011;13(3):347–356. doi: 10.1208/s12248-011-9273-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sayed I.M., Vercouter A.S., Abdelwahab S.F., Vercauteren K., Meuleman P. Is hepatitis E virus an emerging problem in industrialized countries? Hepatology. 2015;62(6):1883–1892. doi: 10.1002/hep.27990. [DOI] [PubMed] [Google Scholar]
  26. Sayed I.M., Verhoye L., Cocquerel L., Abravanel F., Foquet L., Montpellier C., Debing Y., Farhoudi A., Wychowski C., Dubuisson J., Leroux-Roels G., Neyts J., Izopet J., Michiels T., Meuleman P. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut. 2017;66(5):920–929. doi: 10.1136/gutjnl-2015-311109. [DOI] [PubMed] [Google Scholar]
  27. Shiota T., Li T.C., Yoshizaki S., Kato T., Wakita T., Ishii K. The hepatitis E virus capsid C-terminal region is essential for the viral life cycle. implication for viral genome encapsidation and particle stabilization. J. Virol. 2013;87(10):6031–6036. doi: 10.1128/JVI.00444-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Shukla P., Nguyen H.T., Torian U., Engle R.E., Faulk K., Dalton H.R., Bendall R.P., Keane F.E., Purcell R.H., Emerson S.U. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc. Natl. Acad. Sci. U. S. A. 2011;108(6):2438–2443. doi: 10.1073/pnas.1018878108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Canc. 2010;10(4):254–266. doi: 10.1038/nrc2824. [DOI] [PubMed] [Google Scholar]
  30. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes. mechanisms and biological targets. Cell. 2009;136(4):731–745. doi: 10.1016/j.cell.2009.01.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thompson S.R. Tricks an IRES uses to enslave ribosomes. Trends Microbiol. 2012;20(11):558–566. doi: 10.1016/j.tim.2012.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Todt D., Gisa A., Radonic A., Nitsche A., Behrendt P., Suneetha P.V., Pischke S., Bremer B., Brown R.J., Manns M.P., Cornberg M., Bock C.T., Steinmann E., Wedemeyer H. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016;65(10):1733–1743. doi: 10.1136/gutjnl-2015-311000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Todt D., Walter S., Brown R.J., Steinmann E. Mutagenic effects of ribavirin on hepatitis E virus-viral extinction versus selection of fitness-enhancing mutations. Viruses. 2016;8(10) doi: 10.3390/v8100283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. van de Garde M.D., Pas S.D., van der Net G., Man R.A. de, Osterhaus A.D., Haagmans B.L., Boonstra A., Vanwolleghem T. Hepatitis E virus (HEV) genotype 3 infection of human liver chimeric mice as a model for chronic HEV infection. J. Virol. 2016;90(9):4394–4401. doi: 10.1128/JVI.00114-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wedemeyer H., Pischke S., Manns M.P. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology. 2012;142(6):1388–1397. doi: 10.1053/j.gastro.2012.02.014. e1. [DOI] [PubMed] [Google Scholar]
  36. Wu X., Dao Thi V.L., Liu P., Takacs C.N., Xiang K., Andrus L., Gouttenoire J., Moradpour D., Rice C.M. Pan-genotype hepatitis E virus replication in stem cell-derived hepatocellular systems. Gastroenterology. 2018;154(3):663–674. doi: 10.1053/j.gastro.2017.10.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zhao L., Au J.L., Wientjes M.G. Comparison of methods for evaluating drug-drug interaction. Front. Biosci. (Elite Ed) 2010;2:241–249. doi: 10.2741/e86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Zhou X., Xu L., Wang Y., Wang W., Sprengers D., Metselaar H.J., Peppelenbosch M.P., Pan Q. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antivir. Res. 2015;124:11–19. doi: 10.1016/j.antiviral.2015.10.016. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.pdf (270.3KB, pdf)
Multimedia component 2
mmc2.xml (194B, xml)

Articles from Antiviral Research are provided here courtesy of Elsevier

RESOURCES